Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
- DOI
- 10.1007/s00280-026-04960-3
- Published
- 2026 Sep 24
- Container
- Cancer chemotherapy and pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00280-026-04960-3,
title = {Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.},
author = {Önder T and Ateş Ö and Yılmaz ME and Duran AO},
year = {2026},
journal = {Cancer chemotherapy and pharmacology},
doi = {10.1007/s00280-026-04960-3},
url = {https://doi.org/10.1007/s00280-026-04960-3}
}RIS
TY - JOUR TI - Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. AU - Önder T AU - Ateş Ö AU - Yılmaz ME AU - Duran AO PY - 2026 JO - Cancer chemotherapy and pharmacology DO - 10.1007/s00280-026-04960-3 UR - https://doi.org/10.1007/s00280-026-04960-3 ER -
APA
T, Ö., Ö, A., ME, Y., & AO, D. (2026). Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.. Cancer chemotherapy and pharmacology. https://doi.org/10.1007/s00280-026-04960-3
Source records
- pubmed · retrieved 2026-09-25T23:43:48.040Z